Concepedia

Jeff D. Cohen

JD

Statistics

Publications

5

Citations

79

H-Index

5

Active since

2004

Affiliations

Sarah Cannon(Current)

Arizona Oncology

Jeff D. Cohen is an author at Sarah Cannon specializing in chemotherapy, oncology, and clinical pharmacology.

Publications per year

2004–2024

5

Publications

5

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Shripad V. Bhagwat, Cecilia Mur, Matthew Vandekopple et al. · Cancer Research · 2024 · 22 citations · Full text

, , +16

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

Alison Stopeck, SL Moulder, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2007 · 21 citations

, , +15

A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors

Daniel D. Von Hoff, C. Taylor, S. D. Rubin et al. · Journal of Clinical Oncology · 2004 · 14 citations

, , +13

Phase I trial of a novel epothilone, KOS-1584, using a weekly dosing schedule

Alison Stopeck, E.D. Thomas, Suzanne F. Jones et al. · Journal of Clinical Oncology · 2006 · 11 citations

, , +17

A Phase I and pharmacokinetic study of HMN-214, a novel oral polo-like kinase inhibitor, in patients with advanced solid tumors

Daniel D. Von Hoff, Charles Taylor, S. D. Rubin et al. · Journal of Clinical Oncology · 2004 · 11 citations

, , +13

1–5 of 5